Current status of HIV therapy: I. Antiretroviral agents.
The clinician's armamentarium is no longer limited to zidovudine as the only antiretroviral agent that enhances both quality and length of life. ddI has shown clinical benefit in patients previously treated with zidovudine. Recently, the combination of zidovudine and ddC has been approved on the basis of surrogate marker activity; its clinical role awaits results of ongoing trials.